EXEL Quote, Trading Chart, Exelixis Inc.
home / stock / exel / exel quote
$22.86 Last:
2.88% Change Percent:
$22.33 Open:
$22.86 Previous Close:
$22.9 High:
$22.25 Low:
1,327,435 Volume:
06/24/2021 04:41:50 am Last Trade Date Time:
Quotes are delayed by 15 to 20 minutes.
EXEL Last Five Trading Days
| Stock Date | Open Price | Close Price | High | Low | Volume |
|---|---|---|---|---|---|
| 2021-06-24 | 22.33 | 22.86 | 22.9 | 22.25 | 1,327,435 |
| 2021-06-23 | 22.9 | 22.22 | 22.95 | 22.156 | 1,391,946 |
| 2021-06-22 | 22.73 | 22.83 | 22.94 | 22.441 | 1,394,480 |
| 2021-06-21 | 22.48 | 22.74 | 22.77 | 22.19 | 1,436,394 |
| 2021-06-18 | 22.06 | 22.41 | 22.48 | 21.73 | 2,857,699 |
| 2021-06-17 | 22.17 | 22.13 | 22.42 | 21.89 | 1,267,302 |
| 2021-06-16 | 22.6 | 22.43 | 22.762 | 22.16 | 1,046,645 |
| 2021-06-15 | 23.15 | 22.64 | 23.185 | 22.56 | 1,169,677 |
| 2021-06-14 | 23.09 | 22.76 | 23.34 | 22.71 | 1,188,570 |
| 2021-06-11 | 22.85 | 22.98 | 23.1 | 22.795 | 758,109 |
| 2021-06-10 | 22.79 | 22.95 | 23.26 | 22.52 | 1,308,602 |
| 2021-06-09 | 22.4 | 22.78 | 22.8 | 22.24 | 1,314,852 |
| 2021-06-08 | 22.24 | 22.3 | 22.34 | 21.65 | 1,182,449 |
| 2021-06-07 | 22.29 | 22.06 | 22.48 | 21.7 | 1,991,625 |
| 2021-06-04 | 22.32 | 22.37 | 22.685 | 22.2 | 871,703 |
| 2021-06-03 | 22.2 | 22.19 | 22.27 | 21.68 | 1,180,598 |
| 2021-06-02 | 22.82 | 22.33 | 22.95 | 22.11 | 2,250,327 |
| 2021-06-01 | 22.6 | 22.89 | 22.98 | 22.37 | 1,386,623 |
| 2021-05-31 | 22.74 | 22.55 | 23.11 | 22.5 | 1,875,395 |
| 2021-05-28 | 22.74 | 22.55 | 23.11 | 22.5 | 1,874,684 |
News, Short Squeeze, Breakout and More Instantly...
-
Exelixis, Inc. (Nasdaq: EXEL) announced that, effective today, Gisela M. Schwab, M.D., the company’s President, Product Development and Medical Affairs and Chief Medical Officer, has begun a medical leave of absence. Dr. Schwab will remain available to advise Exelixis as need...
-
– Expansion cohorts to include patients with advanced kidney, prostate and bladder cancers – Exelixis, Inc. (Nasdaq: EXEL) today announced a clinical trial collaboration and supply agreement with Bristol-Myers Squibb Company (NYSE: BMY) for STELLAR-002,...
-
– New findings demonstrate the significant progression-free survival benefit seen in the intent-to-treat population was also consistent across subgroups – – Results from COSMIC-311 served as basis for Exelixis’ recent supplemental New Drug App...